Mounjaro vs Ozempic: Which Weight Loss Treatment Is Better?

Mounjaro produces greater average weight loss than Ozempic in clinical trials. But Ozempic has landmark cardiovascular outcome data that Mounjaro does not yet have. Here is the complete comparison to help patients in Srinagar make an informed decision with their physician.

Are Mounjaro and Ozempic the same type of drug?

Both Mounjaro and Ozempic belong to the broad class of incretin-based therapies. Both mimic the action of GLP-1 — the gut hormone that regulates blood sugar and appetite. But they are not identical. Ozempic contains semaglutide, which is a GLP-1 receptor agonist activating one hormonal pathway. Mounjaro contains tirzepatide, which is a dual GIP plus GLP-1 receptor agonist activating two hormonal pathways simultaneously. This dual activation is why Mounjaro generally produces greater weight loss and blood sugar reduction. Both are once-weekly subcutaneous injections using pre-filled auto-injector pens, and both require a prescription and physician supervision. For a full explanation of how GLP-1 works and why these medications matter, see: What is GLP-1 and why is everyone talking about it?.

Weight loss: how do they compare?

In the STEP 1 trial, semaglutide 2.4 mg produced average weight loss of 14.9% of body weight at 68 weeks in adults with obesity but no diabetes. In the SURMOUNT-1 trial, tirzepatide 15 mg produced average weight loss of 20.9% of body weight at 72 weeks in the same population. For a person weighing 100 kg, that is the difference between losing approximately 15 kg and losing approximately 21 kg. A published analysis in JAMA Internal Medicine in 2024 using real-world clinical data confirmed tirzepatide-treated patients lost significantly more weight than semaglutide-treated patients at 6 and 12 months. For maximum weight loss, tirzepatide (Mounjaro) has the superior clinical trial and real-world evidence base. Both medications should only be used under physician supervision following baseline blood tests arranged via home collection in Srinagar.

Blood sugar control: which wins?

Both medications are approved for type 2 diabetes management and produce excellent HbA1c reductions. Semaglutide reduces HbA1c by approximately 1.5 to 1.8 percentage points on average. Tirzepatide reduces HbA1c by approximately 1.8 to 2.4 percentage points, dose-dependently. The SURPASS-2 trial directly compared tirzepatide to semaglutide in people with type 2 diabetes and found tirzepatide superior at all doses tested. For patients with type 2 diabetes who want both maximum blood sugar control and maximum weight loss, tirzepatide has the more robust head-to-head evidence. Monitor your blood sugar response to either treatment with regular HbA1c testing at home. See our guide on managing diabetes at home in Kashmir for broader diabetes management context.

Cardiovascular outcomes: a critical difference

This is where the comparison becomes more nuanced — and where semaglutide currently has a significant evidence advantage. The SELECT trial published in the New England Journal of Medicine in 2023 demonstrated that semaglutide 2.4 mg reduced major cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% in adults with obesity and established cardiovascular disease. This is landmark-level evidence and semaglutide is the first obesity medication with such a large prospective randomised cardiovascular outcome trial showing mortality benefit. The dedicated cardiovascular outcome trial for tirzepatide is ongoing with results anticipated in 2025 to 2026. Preliminary metabolic data is very promising, but the hard endpoint trial data is not yet published. For patients where cardiovascular risk reduction is the primary clinical goal — for example someone with established heart disease or with elevated Lp(a) and elevated ApoB — semaglutide's cardiovascular data may tip the balance until tirzepatide's trial is published.

Side effects: are they different?

The side effect profiles of both medications are broadly similar, reflecting their shared GLP-1 mechanism. Both primarily cause gastrointestinal side effects — nausea, diarrhoea, vomiting, and constipation — that are most pronounced during dose escalation and typically improve significantly over time. Both carry the same animal-study-based thyroid cancer warning and the same pancreatitis warning. Neither causes significant hypoglycaemia when used alone; the risk increases when combined with insulin or sulphonylureas, requiring dose adjustment of those medications. Some patients tolerate one better than the other individually, but there is no consistent published evidence that one is significantly more tolerable at equivalent dosing. Gallbladder disease associated with rapid weight loss is reported with both. Maintaining physical activity and protein intake helps preserve muscle — physiotherapy in Srinagar can support patients through structured exercise during treatment.

Which is right for you?

For obesity without diabetes where maximum weight loss is the priority, tirzepatide (Mounjaro) has the superior evidence base if available and tolerated. For established cardiovascular disease combined with obesity, semaglutide's SELECT cardiovascular data may favour it, especially until tirzepatide's cardiovascular trial is published — discuss with your cardiologist. For type 2 diabetes combined with obesity where maximum benefit in both endpoints is the goal, tirzepatide is superior in head-to-head trials. This guidance is for educational purposes only. The right medication must be determined by a qualified physician who has reviewed your full medical history, current medications, and cardiovascular risk profile. Baseline tests before starting either medication — HbA1c, kidney function, liver function, and lipid panel — are all available via home collection in Srinagar. Book a doctor home visit to discuss your options.